Moderna shares rise 5.97% after-hours after raising 2025 revenue forecast to $1.9B and outlining expense cuts.

Moderna (MRNA) rose 5.97% in after-hours trading following the company's announcement to raise its 2025 revenue forecast to $1.9 billion, alongside significant operating expense reductions and a reaffirmed path toward cash breakeven by 2028. The update, disclosed in early 2026, highlighted progress in late-stage vaccines and oncology programs, prompting analysts and investors to reassess the stock's risk-re.